- Home
- URGN vs MDXG Comparison
URGN vs MDXG Comparison
Compare URGN & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- MDXG
- Stock Information
- Founded
- URGN 2004
- MDXG 2006
- Country
- URGN United States
- MDXG United States
- Employees
- URGN N/A
- MDXG N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- URGN Health Care
- MDXG Health Care
- Exchange
- URGN Nasdaq
- MDXG Nasdaq
- Market Cap
- URGN 1.1B
- MDXG 1.0B
- IPO Year
- URGN 2017
- MDXG N/A
- Fundamental
- Price
- URGN $27.39
- MDXG $6.92
- Analyst Decision
- URGN Strong Buy
- MDXG Buy
- Analyst Count
- URGN 8
- MDXG 1
- Target Price
- URGN $28.50
- MDXG $12.00
- AVG Volume (30 Days)
- URGN 1.4M
- MDXG 1.3M
- Earning Date
- URGN 11-06-2025
- MDXG 10-29-2025
- Dividend Yield
- URGN N/A
- MDXG N/A
- EPS Growth
- URGN N/A
- MDXG N/A
- EPS
- URGN N/A
- MDXG 0.27
- Revenue
- URGN $96,516,000.00
- MDXG $393,442,000.00
- Revenue This Year
- URGN $35.07
- MDXG $19.01
- Revenue Next Year
- URGN $117.83
- MDXG $2.36
- P/E Ratio
- URGN N/A
- MDXG $25.10
- Revenue Growth
- URGN 8.00
- MDXG 14.77
- 52 Week Low
- URGN $3.42
- MDXG $5.79
- 52 Week High
- URGN $27.98
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- URGN 74.68
- MDXG 46.99
- Support Level
- URGN $24.69
- MDXG $6.45
- Resistance Level
- URGN $26.28
- MDXG $7.51
- Average True Range (ATR)
- URGN 1.87
- MDXG 0.30
- MACD
- URGN 0.32
- MDXG -0.08
- Stochastic Oscillator
- URGN 95.93
- MDXG 37.30
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.